NumFin

ARCA biopharma, Inc.

Simbol: ABIO

NASDAQ

3.26

USD

Tržna cena danes

  • -8.6266

    Razmerje P/E

  • -0.1918

    Razmerje PEG

  • 47.29M

    Kapaciteta MRK

  • 0.00%

    Donos DIV

ARCA biopharma, Inc. (ABIO) Finančni izkazi

Download
LetniČetrtletno
LinearnoLog
Na grafu so prikazane privzete številke v dinamiki za ARCA biopharma, Inc. (ABIO). Prihodki podjetja prikazujejo povprečje 5.652 M, ki je 1.153 % gowth. Povprečni bruto dobiček za celotno obdobje je 5.979 M, ki je 0.795 %. Povprečno razmerje bruto dobička je 0.538 %. Rast čistega dobička za lanskoletno poslovanje podjetja je -0.423 %, kar je enako -0.189 % % v povprečju v celotni zgodovini podjetja.,

LetniČetrtletno
10Y20Y30Y40Y

Bilanca stanja

Če pogledamo fiskalno pot podjetja ARCA biopharma, Inc., opazimo povprečno rast sredstev. Zanimivo je, da ta stopnja znaša , kar odraža tako visoke kot tudi padce podjetja. Pri primerjavi četrtletja s četrtletjem se ta številka prilagodi na 0. Pogled nazaj v preteklo leto razkrije skupno spremembo sredstev v višini -0.121. Na področju kratkoročnih sredstev ABIO znaša 37.592 v valuti poročanja. Velik del teh sredstev, natančneje 37.431, je v denarju in kratkoročnih naložbah. V tem segmentu se je ob primerjavi s podatki za preteklo leto spremenil za -0.118%. Dolgoročne naložbe podjetja, ki sicer niso v središču njegovega zanimanja, znašajo 0, če obstajajo, v valuti poročanja. To pomeni razliko v višini 0.000% glede na zadnje obdobje poročanja, kar odraža strateške premike družbe. Dolgoročni profil podjetja kaže skupni dolgoročni dolg v višini 0.204 v valuti poročanja. Ta številka pomeni medletno spremembo v višini 0.000%. Vrednost za delničarje, kot jo prikazuje celotni lastniški kapital, je ovrednotena z vrednostjo 37.02 v valuti poročanja. Letna sprememba tega vidika je -0.112%. Podrobnejši pregled finančnih podatkov podjetja razkrije dodatne podrobnosti. Neto terjatve so ovrednotene na 0, zaloge na 0, dobro ime pa na 0, če obstaja. Celotna neopredmetena sredstva, če so prisotna, so ovrednotena z vrednostjo 0.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

balance-sheet.row.cash-and-short-term-investments

151.9837.442.453.4
49.1
8.4
6.6
11.8
21.2
38.8
15.4
16.8
2.9
5.9
7
7.8
51
97.6
153.1
70.3
50.6
34.2
2.2
12.3
2.7
30.7
21.6
23.2
6.7

balance-sheet.row.short-term-investments

0000
0
0
0
3
13.8
0
0
0
0
0
0
0
15.1
65.5
92.8
32.6
33.8
21
0
0
0
17
0
0
0

balance-sheet.row.net-receivables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0.6
8.6
0.1
0.3
0.3
0.6
1.1
0
1.3
0.7
2.2
0.1

balance-sheet.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12.3
12.6
0
0
1.9
0
0
0
0
0

balance-sheet.row.other-current-assets

1.930.20.31.1
0.9
0.1
0.2
0.5
0.3
0.1
0.1
0.2
0.1
0.3
0.1
0.5
0.7
1.8
4.7
3.1
2.5
5.3
3
1
2.9
1
25.9
34.8
0.4

balance-sheet.row.total-current-assets

153.9137.642.754.4
50
8.5
6.8
12.3
21.4
38.9
15.5
16.9
3
6.2
7.2
8.3
52.1
100
166.3
85.8
66
39.9
5.9
16.3
5.6
33
48.2
60.2
7.2

balance-sheet.row.property-plant-equipment-net

0.870.30.40.5
0.4
0
0
0
0.1
0
0
0
0
0.1
0.7
1
6.8
8.9
12
15.2
6
10
15.1
19
12.5
8.4
6.9
3.9
1.6

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
4.7
4.7
4.7
4.7
4.7
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7.1
7
7.5
2.1
3
1.1
1.8
0.7
0.7
0.6

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
4.7
4.7
7.1
7
7.5
2.1
3
1.1
1.8
0.7
0.7
0.6

balance-sheet.row.long-term-investments

0000
0
0
0
0
2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.05000
0
0
0
0
0.8
0.6
0.6
0.1
0.1
0.2
0.3
0.1
7.1
7.1
1.4
0
0.2
0.5
3.9
1.6
2.1
2.2
2.1
2.2
0

balance-sheet.row.total-non-current-assets

0.930.30.40.5
0.5
0.1
0
0.1
3.2
0.7
0.6
0.2
0.2
0.3
1
1.1
13.9
20.7
18.1
22.3
13.3
18
21.2
23.6
15.7
12.4
9.7
6.8
2.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

154.8337.943.154.9
50.4
8.5
6.8
12.4
24.6
39.6
16.1
17.1
3.2
6.5
8.2
9.4
66
120.7
184.4
108
79.3
57.8
27.1
39.9
21.3
45.4
57.9
67
9.4

balance-sheet.row.account-payables

1.450.40.31.1
1.8
0.4
0.2
0.6
1.2
0.4
0.8
0.6
0.1
0.3
0.4
0.5
1.3
2.8
7
4.9
3.1
1.7
2.2
3.2
2
1.5
1.9
1.6
0.6

balance-sheet.row.short-term-debt

0.290.10.10.1
0
0
0
0
0
0
0
0
0
0
0
0
8
13
3.7
8.3
4.4
4.7
1.2
2.5
2.4
2.1
1.4
0.3
0.3

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0.670.20.30.4
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
3.8
11.1
15.5
5
6.2
4.7
5.2
4.5
0.6
0.8

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
0.2
0.3
5
16.1
44.5
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

3.840.60.82.4
1.7
0.5
0.6
1.4
1.2
1.1
0.6
0.9
0.2
0.5
0.7
1
0.4
2.2
29.5
29.9
10.5
5.6
22.6
8.6
3.8
7.3
2.6
1.5
0.3

balance-sheet.row.total-non-current-liabilities

0.670.20.30.4
0.4
0
0
0
0
0
0
0
0
0
0.2
0.3
12.2
34.8
70.7
6.4
11.1
21
5
6.4
4.7
5.3
4.4
0.7
0.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0.670.20.30.4
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
1.1
1
2.2
0
0
0
0
0

balance-sheet.row.total-liab

5.480.81.43.9
3.9
0.9
0.8
2.1
2.4
1.5
1.4
1.5
0.3
0.8
1.4
2
23.5
53
114.6
51.3
33.7
35.1
31.6
24.4
12.9
16.2
10.3
4.1
2

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14.8

balance-sheet.row.common-stock

0.06000
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0.1
0
0
0
0
0
0
82.5
0
0
0

balance-sheet.row.retained-earnings

-753.37-188.7-183.4-173.5
-154.2
-144.4
-138.9
-131
-112.5
-96.1
-84.6
-74.9
-68
-63.7
-58.3
-49.9
-500.4
-470.5
-458.2
-327.7
-256
-203.6
-153.4
-108.4
-71.9
-49.7
-31.1
-14.8
-8.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
0
0
0
-0.4
-0.4
-0.5
-0.5
-0.5
-1
-0.6
0
0
0
-0.3
-0.2
0
0
-0.1
0
-3.6
-3
-1.3
-0.5

balance-sheet.row.other-total-stockholders-equity

902.67225.7225.1224.5
200.7
152
145
141.3
134.7
134.5
99.7
91
71.4
69.9
66
57.9
542.9
538.1
528
384.6
301.8
226.3
148.8
123.8
80.3
0
81.7
79
16.1

balance-sheet.row.total-stockholders-equity

149.353741.751
46.5
7.6
6
10.3
22.2
38.1
14.7
15.6
2.9
5.7
6.8
7.4
42.5
67.7
69.8
56.8
45.6
22.7
-4.6
15.4
8.4
29.2
47.6
62.9
7.4

balance-sheet.row.total-liabilities-and-stockholders-equity

154.8337.943.154.9
50.4
8.5
6.8
12.4
24.6
39.6
16.1
17.1
3.2
6.5
8.2
9.4
66
120.7
184.4
108
79.3
57.8
27.1
39.9
21.3
45.4
57.9
67
9.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0

balance-sheet.row.total-equity

149.353741.751
46.5
7.6
6
10.3
22.2
38.1
14.7
15.6
2.9
5.7
6.8
7.4
42.5
67.7
69.8
56.8
45.6
22.7
-4.6
15.5
8.4
29.2
47.6
62.9
7.4

balance-sheet.row.total-liabilities-and-total-equity

154.83---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0000
0
0
0
3
16.1
0
0
0
0
0
0
0
15.1
65.5
92.8
32.6
33.8
21
0
0
0
17
0
0
0

balance-sheet.row.total-debt

0.720.30.30.4
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
3.8
12.1
15.5
20.2
6.2
8.7
7.1
7.3
5.9
0.9
1.1

balance-sheet.row.net-debt

-151.26-37.2-42.2-53
-48.7
-8.3
-6.6
-8.7
-7.4
-38.8
-15.4
-16.8
-2.9
-5.9
-7
-7.8
-35.9
-32.1
-56.6
-25.7
-1.3
7.1
4
-3.6
4.4
-6.4
-15.7
-22.3
-5.6

Izkaz denarnih tokov

V zadnjem obdobju se je v finančnem okolju ARCA biopharma, Inc. opazno spremenil prosti denarni tok, ki se je spremenil v 0.541. Podjetje je nedavno povečalo svoj osnovni kapital z izdajo 0, kar kaže na razliko 0.000 v primerjavi s prejšnjim letom. Zanimivo je, da je del delnic podjetja, natančneje 0, odkupilo podjetje samo. To dejanje je povzročilo spremembo v 0.000 v primerjavi s prejšnjim letom. Medtem pa obveznosti podjetja trenutno znašajo 0.03 v valuti poročanja. Družba je pri naložbenju porabila neto denarna sredstva v višini 0.000 v valuti poročanja. To je premik za 0.000 v primerjavi s prejšnjim letom. V istem obdobju je družba zabeležila 0.11, 0 in 0, ki so pomembne za razumevanje naložbenih in odplačilnih strategij podjetja. Družba je pri financiranju porabila 0.000, pri čemer je razlika v primerjavi z letom prej znašala 0.000. Poleg tega je podjetje namenilo 0 za izplačilo dividend svojim delničarjem. Hkrati je izvajalo tudi druge finančne manevre, imenovane 0, ki so prav tako pomembno vplivali na denarni tok v tem obdobju. Te sestavine skupaj tvorijo celovito sliko finančnega stanja podjetja in strateškega pristopa k upravljanju denarnih tokov.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

cash-flows.row.net-income

-6-5.3-9.9-19.3
-9.7
-5.5
-7.9
-18.5
-16.4
-11.4
-9.7
-6.9
-4.3
-5.4
-8.4
-9.1
-29.9
-12.3
-130.6
-71.6
-52.5
-50.2
-45
-36.5
-22.3
-18.5
-16.4
-6.5
-4.8

cash-flows.row.depreciation-and-amortization

0.10.10.10.1
0.1
0.1
0
0.4
0.3
0
0
0
0
0.6
0.3
0.5
2.3
2.3
3.2
2.7
4.1
5.5
6.3
5.1
3.1
3
2
1.2
0.4

cash-flows.row.deferred-income-tax

-0.77-0.90-1.1
0.9
-0.1
0
0
0
0
0
0
0
3.4
0
-2.3
4.7
0
13.6
1.2
1.5
0.7
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0.60.70.60.5
0
0.2
0.3
0.5
0.6
0.6
0.6
0.3
0.3
0.3
0.5
0.8
4.6
0
11.3
0.6
0.3
0.5
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0.36-0.5-1.70
1.9
0.4
-0.6
0.1
0.4
0.1
-0.4
1.3
-0.1
-0.5
-0.4
-13.1
-28.3
-48.6
53.8
8.1
-1.2
-3.8
22.5
33
9.4
2.6
2.6
-2.8
0.1

cash-flows.row.account-receivables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38.4
0.2
0.1
0.5
-0.6
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12.4
-1.6
-8.6
-28.9
44.8
0
0
0
0
0
0

cash-flows.row.account-payables

0.160-0.8-0.4
1.1
0.2
-0.4
-0.6
0.8
-0.4
0.2
0.5
-0.2
-0.1
-0.1
-2.5
-1
0
2.1
1.8
1
-1.1
-1
0
0
0
0
0
0

cash-flows.row.other-working-capital

0.36-0.5-0.90.4
0.8
0.3
-0.2
0.7
-0.4
0.5
-0.6
0.8
0.1
-0.4
-0.3
-10.7
-27.2
-48.6
0.8
7.8
6.3
25.8
-20.7
33
9.4
2.6
2.6
-2.8
0.1

cash-flows.row.other-non-cash-items

0.920.901.1
-0.9
0.1
0
0.1
0.2
0.2
0.1
0
0
-5.4
-0.3
-18.5
0.1
12.6
11.7
0
-2.3
2.2
-15.1
-23.1
-11.2
-0.1
0.1
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-4.95000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0000
0
0
0
0
0
0
0
0
0
0
0
-0.2
-0.2
-0.4
-2.4
-2.6
-0.7
-0.3
-2.1
-12.6
-8.3
-4.4
-4.6
-3.1
-0.9

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0
0
0
0
0
0
30.4
0
0.1
0
0
0
0.7
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0000
0
0
0
-5.5
-20.5
0
0
0
0
0
0
0
-44.6
-116.6
-114.6
-62.8
-63.8
-20.2
0
0
-57.1
-16.4
-44.5
-38.9
0

cash-flows.row.sales-maturities-of-investments

0000
0
0
3
18.4
4.1
0
0
0
0
0
0.3
15.1
95
143.9
54.4
64.2
50.9
22.5
0
0
74.1
24.3
53.6
5
0

cash-flows.row.other-investing-activites

0000
0
0
0
0
0
0
0
0
0
2
0
0.3
0
-6
0.5
0
0
25.7
0.5
-0.5
0
0
0
-0.1
0

cash-flows.row.net-cash-used-for-investing-activites

0000
0
0
3
12.9
-16.4
0
0
0
0
2
0.3
45.6
50.2
21.1
-62.1
-1.2
-13.6
28.4
-1.6
-13.1
8.7
3.5
4.5
-37.1
-0.9

cash-flows.row.debt-repayment

0000
-0.4
-0.3
0
0
0
0
0
0
0
0
0
-4
0
0
0
0
0
-2.3
-2.5
0
0
0
0
0
0

cash-flows.row.common-stock-issued

00024.1
50.9
7.3
3.5
6.6
0
37
9
1.7
1.5
4.7
7.7
0.1
0.2
0.4
130
84.3
71.8
28
14.8
22.2
1.5
0.2
0.5
61.5
10.2

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

000-1
-2
-0.4
-0.4
-0.7
0
-3
-1
17.4
-0.5
-0.9
-0.3
0
0
-3.8
-8.3
-3.2
-4.4
1.9
10.5
22.1
-0.2
1.5
5.1
0.1
1

cash-flows.row.net-cash-used-provided-by-financing-activities

00023.1
48.5
6.6
3.1
5.8
0
34
8
19.2
1.1
3.9
7.3
-3.9
0.2
-3.4
121.7
81.2
67.4
27.6
22.8
44.3
1.3
1.6
5.6
61.6
11.2

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-4.95-5-10.94.3
40.7
1.8
-2.1
1.3
-31.4
23.4
-1.4
13.8
-3
-1.1
-0.7
0
3.8
-28.3
22.6
21
3.7
10.9
-10.1
9.6
-11
-7.9
-1.6
16.4
6

cash-flows.row.cash-at-end-of-period

151.9837.442.453.4
49.1
8.4
6.6
8.7
7.4
38.8
15.4
16.8
2.9
5.9
7
7.8
35.9
32.1
60.3
37.8
16.8
13.1
2.2
12.3
2.7
13.7
21.6
23.1
6.8

cash-flows.row.cash-at-beginning-of-period

156.9242.453.449.1
8.4
6.6
8.7
7.4
38.8
15.4
16.8
2.9
5.9
7
7.8
7.7
32.1
60.3
37.8
16.8
13.1
2.2
12.3
2.7
13.7
21.6
23.2
6.7
0.8

cash-flows.row.operating-cash-flow

-4.95-5-10.9-18.8
-7.7
-4.8
-8.2
-17.5
-15
-10.5
-9.4
-5.3
-4.1
-7
-8.3
-41.7
-46.5
-46
-37.1
-59
-50.1
-45.1
-31.3
-21.5
-21
-13
-11.7
-8.1
-4.3

cash-flows.row.capital-expenditure

0000
0
0
0
0
0
0
0
0
0
0
0
-0.2
-0.2
-0.4
-2.4
-2.6
-0.7
-0.3
-2.1
-12.6
-8.3
-4.4
-4.6
-3.1
-0.9

cash-flows.row.free-cash-flow

-4.95-5-10.9-18.8
-7.7
-4.8
-8.2
-17.5
-15
-10.5
-9.4
-5.3
-4.1
-7
-8.3
-41.9
-46.7
-46.3
-39.5
-61.6
-50.8
-45.4
-33.4
-34.1
-29.3
-17.4
-16.3
-11.2
-5.2

Vrstica izkaza poslovnega izida

Prihodki ARCA biopharma, Inc. so se v primerjavi s prejšnjim obdobjem spremenili za 0.000%. Bruto dobiček podjetja ABIO znaša -0.11. Odhodki iz poslovanja podjetja so 7.3 in so se v primerjavi s prejšnjim letom spremenili za -31.144%. Odhodki za amortizacijo znašajo 0.11, kar je -0.026% sprememba glede na zadnje obračunsko obdobje. Stroški poslovanja so sporočeni v višini 7.3, ki kaže -31.144% spremembo glede na preteklo leto. Stroški prodaje in trženja znašajo 0, kar pomeni 0.000% spremembo v primerjavi s preteklim letom. EBITDA na podlagi zadnjih podatkov znaša 0 in predstavlja 0.311% rast v primerjavi s preteklim letom. Prihodki iz poslovanja so -7.3, ki kažejo -0.311% spremembo v primerjavi s preteklim letom. Sprememba čistih prihodkov je -0.423%. Čisti prihodki v zadnjem letu so znašali -5.34.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

income-statement-row.row.total-revenue

0.18000
0
0
0
0
0
0
0
0
0
0
0
0
15.3
46.9
3.9
0.5
0.2
2.3
26.4
24.6
15.6
6.4
9.6
6.2
0.4

income-statement-row.row.cost-of-revenue

0.10.10.10.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3.1
-3
-2
-1.2
-0.4

income-statement-row.row.gross-profit

0.07-0.1-0.1-0.1
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
15.3
46.9
3.9
0.5
0.2
2.3
26.4
24.6
18.7
9.4
11.6
7.4
0.8

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0.79---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

7.19---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

2.3---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0
0
0
0
0
0
0
0
0
-1.3
2.3
24.5
0
0.2
1.2
0
0
3.1
3
2
1.2
0.4

income-statement-row.row.operating-expenses

7.967.310.619.3
9.8
5.8
8.1
18.7
16.6
11.5
9.7
6.9
4.3
7.4
9.2
22.9
41.4
63.4
144.5
73.6
48.8
51.5
68.3
60
41.5
29.3
30.7
15.5
5.8

income-statement-row.row.cost-and-expenses

7.987.310.619.3
9.8
5.8
8.1
18.7
16.6
11.5
9.7
6.9
4.3
7.4
9.2
22.9
41.4
63.4
144.5
73.6
48.8
51.5
68.3
60
38.3
26.3
28.7
14.3
5.4

income-statement-row.row.interest-income

1.9820.70
0
0.2
0.2
0.2
0.2
0
0
0
0
0
0.8
0.2
0
6.7
8.4
2.2
2.9
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

0.4500.70
0
0
0
0
0
0
0
0
0
0
0
0.2
0
-0.1
-0.3
-0.5
-0.5
-1.7
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

2.3---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

1.9820.70
0
0.2
0.2
0.2
0.2
0
0
0
0
2
0.8
11.4
-6.2
-2.3
-24.5
0.3
-0.2
-1.2
-2.1
-0.8
0
0
2.7
1.7
0.3

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0
0
0
0
0
0
0
0
0
-1.3
2.3
24.5
0
0.2
1.2
0
0
3.1
3
2
1.2
0.4

income-statement-row.row.total-operating-expenses

1.9820.70
0
0.2
0.2
0.2
0.2
0
0
0
0
2
0.8
11.4
-6.2
-2.3
-24.5
0.3
-0.2
-1.2
-2.1
-0.8
0
0
2.7
1.7
0.3

income-statement-row.row.interest-expense

0.4500.70
0
0
0
0
0
0
0
0
0
0
0
0.2
0
-0.1
-0.3
-0.5
-0.5
-1.7
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.10.10.10
0
0.3
0
0.4
0.3
0
0
0
0
0.6
0.3
0.5
2.3
2.3
3.2
2.7
4.1
5.5
6.3
5.1
3.1
3
2
1.2
0.4

income-statement-row.row.ebitda-caps

-7.94---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-7.98-7.3-10.6-19.3
-9.8
-5.8
-8.1
-18.7
-16.6
-11.5
-9.7
-6.9
-4.3
-7.4
-9.2
-36.7
-33.3
-18.9
-140.6
-73
-48.6
-49.2
-43.9
-36.2
-22.7
-19.9
-19.1
-8.1
-5

income-statement-row.row.income-before-tax

-6-5.3-9.9-19.3
-9.7
-5.6
-8
-18.6
-16.4
-11.4
-9.7
-6.9
-4.3
-5.4
-8.4
-11.4
-29.9
-12.3
-130.6
-71.6
-52.5
-50.2
-76.8
-36.8
0
0
-16.4
-6.4
-4.7

income-statement-row.row.income-tax-expense

0.45-0.1-0.7-0.1
0
-0.2
0
-0.1
0.2
0
0
0
0
0
0.8
-2.3
3.8
-4.3
-10
-1.4
3.8
0.9
3.1
-0.3
-0.5
-1.4
-2.7
-1.6
-0.2

income-statement-row.row.net-income

-5.48-5.3-9.3-19.2
-9.7
-5.5
-7.9
-18.5
-16.5
-11.4
-9.7
-6.9
-4.3
-5.4
-8.4
-9.1
-29.9
-12.3
-130.6
-71.6
-52.5
-50.2
-45
-36.5
-22.3
-18.5
-16.4
-6.5
-4.8
Podobne delnice
Morda vas zanima tudi:
SRNE
Sorrento Therapeutics, Inc..
0.015 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.97 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
300 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.1 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.35 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Pogosto zastavljeno vprašanje

Kaj je ARCA biopharma, Inc. (ABIO) skupna sredstva?

ARCA biopharma, Inc. (ABIO) skupna sredstva so 37861000.000.

Kakšen je letni prihodek podjetja?

Letni prihodki so 176000.000.

Kolikšna je stopnja dobička podjetja?

Dobiček podjetja je 0.426.

Kakšen je prosti denarni tok podjetja?

Prosti denarni tok je -0.341.

Kolikšna je neto stopnja dobička podjetja?

Čista stopnja dobička je -31.136.

Kolikšni so skupni prihodki podjetja?

Celotni prihodki so -45.352.

Kaj je ARCA biopharma, Inc. (ABIO) čisti dobiček (čisti dobiček)?

Čisti dobiček (čisti prihodek) je -5339000.000.

Kolikšen je skupni dolg podjetja?

Skupni dolg je 280000.000.

Kolikšni so stroški poslovanja?

Stroški poslovanja so 7296000.000.

Kolikšno je število denarnih sredstev podjetja?

Denarna sredstva podjetja so 35903000.000.